Bristol-Myers Squibb Company (BMY)
NYSE: BMY · Real-Time Price · USD
44.55
+0.01 (0.03%)
Oct 9, 2025, 4:00 PM EDT - Market closed
BMY Revenue
Bristol-Myers Squibb Company had revenue of $12.27B in the quarter ending June 30, 2025, with 0.56% growth. This brings the company's revenue in the last twelve months to $47.70B, up 2.57% year-over-year. In the year 2024, Bristol-Myers Squibb Company had annual revenue of $48.30B with 7.32% growth.
Revenue (ttm)
$47.70B
Revenue Growth
+2.57%
P/S Ratio
1.90
Revenue / Employee
$1,398,944
Employees
34,100
Market Cap
90.69B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 48.30B | 3.29B | 7.32% |
Dec 31, 2023 | 45.01B | -1.15B | -2.50% |
Dec 31, 2022 | 46.16B | -226.00M | -0.49% |
Dec 31, 2021 | 46.39B | 3.87B | 9.09% |
Dec 31, 2020 | 42.52B | 16.37B | 62.62% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 422.82B |
Johnson & Johnson | 90.63B |
Merck & Co. | 63.62B |
AbbVie | 58.33B |
AstraZeneca | 56.50B |
Novartis AG | 55.19B |
Eli Lilly and Company | 53.26B |
Novo Nordisk | 49.11B |
BMY News
- 4 hours ago - Bristol-Myers Squibb: Your Chance To Buy A Bargain 6% Yield - Seeking Alpha
- 3 days ago - My Top 5 Biotech Stocks Big Pharma Could Buy Next - Seeking Alpha
- 8 days ago - Wall Street's Most Accurate Analysts Weigh In On 3 Health Care Stocks With Over 4% Dividend Yields - Benzinga
- 8 days ago - Bristol Myers Squibb's Anti-MTBR-Tau-Targeting Antibody, BMS-986446, Granted Fast Track Designation by U.S. FDA for the Treatment of Alzheimer's Disease - Business Wire
- 8 days ago - Bristol Myers, Takeda to pool data for AI-based drug discovery - Reuters
- 9 days ago - 7 Ideal "Safer" Dividend Buys From 61 September Graham Value All-Stars (GVAS) - Seeking Alpha
- 11 days ago - Buy 7 Barron's Better Bets (Than T-Bills) From 15 'Safer' Of 23 September Dividend Dogs - Seeking Alpha
- 14 days ago - Bristol Myers to sell psoriasis drug at over 80% discount - Reuters